VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XRAY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
XRAYDENTSPLY SIRONA Inc.
$10.82$2.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksXRAYFinancials

DENTSPLY SIRONA Inc. (XRAY) Financials

30Y historyFree accessUpdated daily

Revenue growth remains stagnant at 0.1% in 2026Q1, while gross margins have compressed to 48.5% from historical peaks exceeding 53%.

XRAY Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue3.68B3.68B3.79B3.96B3.92B4.23B3.34B4.02B3.99B3.99B3.75B2.67B2.92B2.95B2.93B2.54B2.22B2.16B2.19B2.01B1.81B1.72B1.69B1.57B1.51B1.13B889.8M830.9M795.1M720.8M656.6M
Revenue Growth %-1.02%-2.98%-4.34%1.1%-7.3%26.71%-16.98%0.9%-0.18%6.62%40.05%-8.5%-0.95%0.76%15.4%14.26%2.83%-1.54%9.15%11.01%5.56%1.23%7.85%3.78%34.07%26.89%7.09%4.5%10.31%9.78%14.79%
Cost of Goods Sold1.88B1.84B1.83B1.88B1.79B1.88B1.68B1.86B1.92B1.8B1.74B1.16B1.32B1.37B1.37B1.26B1.09B1.05B1.04B969.05M881.49M846.12M847.71M797.72M780.84M559.42M384.84M359.3M341.2M319.6M303.8M
COGS % of Revenue-50%48.38%47.39%45.77%44.53%50.4%46.2%48.13%45.2%46.58%43.27%45.26%46.54%46.85%49.82%49.12%48.55%47.49%48.22%48.69%49.33%50.04%50.78%51.58%49.55%43.25%43.24%42.91%44.34%46.27%
Gross Profit1.8B1.84B1.96B2.09B2.13B2.35B1.66B2.16B2.07B2.19B2B1.52B1.6B1.58B1.56B1.27B1.13B1.11B1.15B1.04B929.01M869.02M846.52M773.2M732.9M569.67M504.95M471.6M453.9M401.2M352.8M
Gross Margin %48.93%50%51.62%52.61%54.23%55.47%49.6%53.8%51.87%54.8%53.42%56.73%54.74%53.46%53.15%50.18%50.88%51.45%52.51%51.78%51.31%50.67%49.96%49.22%48.42%50.45%56.75%56.76%57.09%55.66%53.73%
Gross Profit Growth %--6.03%-6.14%-1.93%-9.37%41.73%-23.47%4.65%-5.52%9.38%31.88%-5.16%1.42%1.35%22.22%12.68%1.7%-3.53%10.68%12.03%6.9%2.66%9.48%5.5%28.65%12.82%7.07%3.9%13.14%13.72%16.71%
Operating Expenses1.58B1.59B2.84B2.17B3.06B1.74B1.66B1.81B1.72B1.67B1.52B1.08B1.14B1.14B1.15B936.85M738.9M723.23M739.17M680.54M602.98M563.34M544.26M501.52M479.13M391.31M341.09M322M312.6M268.7M233.3M
OpEx % of Revenue-43.15%74.8%54.75%78.12%41.1%49.69%45.03%43.13%41.94%40.66%40.28%39.11%38.8%39.23%36.92%33.27%33.48%33.69%33.86%33.3%32.85%32.12%31.92%31.65%34.66%38.33%38.75%39.32%37.28%35.53%
Selling, General & Admin1.44B1.44B1.6B1.61B1.59B1.55B1.3B1.59B1.72B1.67B1.52B1.08B1.14B1.14B1.15B936.85M738.9M723.23M739.17M675.37M606.41M563.34M544.26M501.52M479.13M386.24M299.73M282.4M275.1M236.3M205.2M
SG&A % of Revenue-39.08%42.31%40.68%40.52%36.66%38.99%39.46%43.13%41.94%40.66%40.28%39.11%38.8%39.23%36.92%33.27%33.48%33.69%33.6%33.49%32.85%32.12%31.92%31.65%34.21%33.69%33.99%34.6%32.78%31.25%
Research & Development158M150M165M184M174M171M123M143M160.5M151.7M128.5M74.9M80.8M85.1M85.4M0000000000000000
R&D % of Revenue-4.08%4.35%4.64%4.44%4.04%3.68%3.56%4.03%3.8%3.43%2.8%2.76%2.88%2.92%----------------
Other Operating Expenses001.07B374M1.3B17M234M81M1.33B2.07B44.1M81.2M11.1M13.4M-490K00000-3.43M00005.07M41.36M39.6M37.5M32.4M28.1M
Operating Income151M252M-879M-85M-937M608M-3M353M-958.1M-1.59B454.7M375.2M445.6M419.17M381.94M300.73M380.27M381.19M380.42M354.89M314.79M72.92M295.13M267.98M256.5M178.36M163.86M149.6M141.3M132.5M119.5M
Operating Margin %4.1%6.85%-23.17%-2.14%-23.89%14.37%-0.09%8.78%-24.03%-39.7%12.14%14.03%15.25%14.21%13.04%11.85%17.12%17.65%17.34%17.66%17.39%4.25%17.42%17.06%16.94%15.8%18.42%18%17.77%18.38%18.2%
Operating Income Growth %-128.67%-934.12%90.93%-254.11%20366.67%-100.85%136.84%39.56%-448.65%21.19%-15.8%6.31%9.75%27%-20.92%-0.24%0.2%7.19%12.74%331.69%-75.29%10.13%4.48%43.81%8.85%9.53%5.87%6.64%10.88%18.67%
EBITDA424M604M-530M258M-609M954M331M676M-627.3M-1.27B726.4M498.1M574.68M547.07M511.14M385.76M446.61M446.36M437.35M405.18M362.23M123.48M344.43M313.64M300.36M232.7M205.22M189.2M178.8M164.9M147.6M
EBITDA Margin %11.52%16.41%-13.97%6.51%-15.53%22.55%9.91%16.81%-15.74%-31.77%19.39%18.63%19.66%18.54%17.45%15.2%20.11%20.67%19.94%20.16%20.01%7.2%20.33%19.97%19.84%20.61%23.06%22.77%22.49%22.88%22.48%
EBITDA Growth %182.17%213.96%-305.43%142.36%-163.84%188.22%-51.04%207.76%50.56%-274.68%45.83%-13.33%5.05%7.03%32.5%-13.62%0.06%2.06%7.94%11.86%193.34%-64.15%9.81%4.42%29.08%13.39%8.47%5.82%8.43%11.72%20.79%
D&A (Non-Cash Add-back)273M352M349M343M328M346M334M323M330.8M316.4M271.7M122.9M129.08M127.9M129.2M85.03M66.34M65.17M56.93M50.29M47.43M50.56M49.3M45.66M43.86M54.33M41.36M39.6M37.5M32.4M28.1M
EBIT-461M-398M-867M-94M-990M606M-4M365M-921M-1.57B476.8M385.6M446.17M416.98M387.53M299.93M373.65M385.25M388M381.92M326.03M305.68M302.25M271.68M253.77M178.36M163.86M149.6M141.2M132.5M119.5M
Net Interest Income-66M-88M-69M-81M-65M-61M-61M-27M-35M-35.9M-33.9M-53.7M-41.3M-41.5M-48.09M-35.58M-20.84M-16.86M-15.44M2.65M1.68M-8.77M-19.63M-24.2M00-9.29M0000
Interest Income0000001M2.4M2.1M2.4M2M2.2M5.59M8.12M8.76M9.46M4.25M5.03M17.09M26.43M12.48M9.01M5.47M1.87M00862K0000
Interest Expense90M88M69M81M65M61M62M29.4M37.3M38.3M35.9M55.9M46.91M49.63M56.85M44.62M25.09M17.83M32.53M11.98M10.8M17.77M25.1M26.08M38.18M010.15M8.5M157.1M8.1M6M
Other Income/Expense-723M-738M-57M-90M-118M-63M-47M-15M-400K-41.2M-13.8M-45.5M-41.23M-49.87M-51.26M-44.62M-22.62M-17.83M-24.95M3.24M43K-234.64M-20.98M-16.79M-35.52M6.76M-12.06M-11.5M-86.1M-10.4M-8.6M
Pretax Income-572M-486M-936M-175M-1.05B545M-50M338M-958.4M-1.63B440.9M329.7M404.37M369.33M330.68M256.11M357.66M363.36M355.47M358.13M314.84M71.04M274.15M251.2M220.99M185.13M151.8M138.1M55.1M122.1M110.9M
Pretax Margin %-15.54%-13.21%-24.68%-4.41%-26.9%12.88%-1.5%8.4%-24.04%-40.73%11.77%12.33%13.84%12.52%11.29%10.09%16.1%16.82%16.2%17.82%17.39%4.14%16.18%15.99%14.6%16.4%17.06%16.62%6.93%16.94%16.89%
Income Tax55M112M-26M-43M-105M134M23M82M52.5M-53.2M9.5M77M81.12M52.15M8.92M-11.02M89.22M88.94M71.6M98.48M91.12M25.63M63.87M81.34M73.03M63.63M50.78M48.2M20.3M47.5M43.7M
Effective Tax Rate %-9.62%-23.05%2.78%24.57%9.95%24.59%-46%24.26%-5.48%3.27%2.15%23.35%20.06%14.12%2.7%-4.3%24.95%24.48%20.14%27.5%28.94%36.07%23.3%32.38%33.05%34.37%33.45%34.9%36.84%38.9%39.4%
Net Income-628M-598M-910M-132M-950M411M-73M256M-1.01B-1.55B429.9M251.2M322.85M313.19M314.21M244.52M265.71M274.26M283.87M259.65M223.72M45.41M253.16M174.18M147.95M121.5M101.02M89.9M34.8M74.6M67.2M
Net Margin %-17.06%-16.25%-23.99%-3.33%-24.22%9.71%-2.19%6.37%-25.36%-38.81%11.48%9.39%11.05%10.61%10.73%9.64%11.96%12.7%12.94%12.92%12.36%2.65%14.94%11.09%9.77%10.76%11.35%10.82%4.38%10.35%10.23%
Net Income Growth %30.84%34.29%-589.39%86.11%-331.14%663.01%-128.52%125.32%34.77%-460.55%71.14%-22.19%3.08%-0.32%28.5%-7.97%-3.12%-3.39%9.33%16.06%392.63%-82.06%45.34%17.73%21.78%20.27%12.36%158.33%-53.35%11.01%24.44%
Net Income (Continuing)-627M-598M-910M-132M-950M411M-73M256M-1.01B-1.55B431.4M251.1M322.9M318.2M321.76M247.45M268.43M274.41M283.27M259.71M223.86M45.41M210.29M169.85M147.95M121.5M101.02M89.9M34.8M74.6M67.2M
Discontinued Operations000000000000003.27M0000000223K00000000
Minority Interest01M1M1M1M1M3M2M11.9M11.6M11.6M1.4M919K42.92M40.74M36.07M70.53M74.85M0296K222K188K600K418K1.26M437K4.56M2.5M2.7M4M4.3M
EPS (Diluted)-3.14-3.00-4.48-0.62-4.411.87-0.381.17-4.51-6.861.941.762.242.162.181.701.821.831.871.681.410.281.551.090.930.770.650.560.220.460.42
EPS Growth %30.61%33.04%-622.58%85.94%-335.83%592.11%-132.48%125.94%34.26%-453.61%10.23%-21.43%3.7%-0.92%28.24%-6.59%-0.55%-2.14%11.31%19.15%403.57%-81.94%42.2%17.2%20.78%18.46%16.07%154.55%-52.17%9.52%27.27%
EPS (Basic)--3.00-4.48-0.62-4.411.88-0.381.18-4.51-6.861.971.792.282.202.221.731.851.851.901.711.440.291.581.110.950.780.650.570.220.460.42
Diluted Shares Outstanding199.9M199.4M203.2M212M215.5M220.2M219.2M224.4M224.3M229.4M221.6M142.5M144.2M145M143.94M143.55M145.99M150.1M151.68M154.72M158.27M162.02M164.03M161.29M159.99M157.95M157.12M158.73M160.79M162.69M161.52M
Basic Shares Outstanding199.9M199.4M203.2M212M215.5M218.4M219.2M223.1M224.17M229.29M218M140M141.7M142.7M141.85M141.39M143.98M148.32M149.07M151.71M155.23M159.19M160.77M157.65M156.36M155.34M155.57M158.26M159.99M161.81M161.52M
Dividend Payout Ratio-----22.38%-31.64%--15.03%15.92%11.55%11.11%10%11.71%10.94%10.88%9.49%9.68%9.77%42.15%6.25%8.61%9.7%11.71%12.87%13.19%31.61%13.67%13.24%

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent Structural Impairment Charges

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Top Line Growth Remains Stagnant

According to recent quarterly filings, XRAY's revenue growth has struggled to maintain positive momentum, with the most recent period showing a marginal 0.1% increase, reflecting the broader challenges in sustaining demand across its core dental equipment and consumables segments in a high-interest rate environment.

The lack of meaningful top-line expansion suggests that the company is struggling to offset the cyclical downturn in dental office capital expenditures. Investors should monitor whether this stagnation is a temporary reflection of macroeconomic headwinds or a more permanent loss of market share to value-tier competitors.

Gross Margin Erosion Signals Pressure

As reported in financial statements, XRAY's gross margin has compressed to 48.5% in 2026Q1, down from historical peaks above 53%, indicating that the company is facing significant difficulty in maintaining pricing power amidst intensifying competition and rising input costs for its specialized dental hardware.

This margin contraction implies that the company's premium positioning is being challenged, potentially forcing management to choose between volume loss or further price concessions. The inability to defend these margins suggests that the competitive moat provided by the CEREC ecosystem may be narrowing in the face of commoditization.

Earnings Quality Obscured by Impairments

Based on XRAY's reported figures, the persistent gap between operating income and net income, highlighted by a net loss of $10 million in 2026Q1, suggests that recurring non-cash charges and restructuring costs continue to severely distort the company's underlying operational profitability and earnings potential.

The frequent appearance of large negative net income figures indicates that the company is likely still absorbing the impact of past acquisition failures, such as the Byte divestiture. This pattern warrants further investigation into whether these charges are truly non-recurring or if they represent a fundamental flaw in capital allocation strategy.

Overhead Efficiency Remains Elusive

Data from recent income statements reveals that SG&A expenses remain stubbornly high at $351 million, representing a significant portion of revenue that prevents the company from achieving consistent operating leverage, even during periods where gross profit shows signs of stabilization or slight recovery.

The failure to scale SG&A relative to revenue suggests that the company's current organizational structure is bloated and potentially inefficient. Management's inability to streamline these costs implies that the integration of disparate business units remains a significant drag on the firm's path to sustainable profitability.

Structural Risks to Turnaround Narrative

As evidenced by the volatile net margin profile, which reached a low of -51.9% in 2024Q3, the primary risk for investors is that the company's current restructuring efforts may fail to address the fundamental decline in its high-margin equipment segment's long-term competitive relevance.

Short-sellers would likely focus on the recurring nature of these impairments as evidence that the company's asset base is overvalued. If the firm cannot demonstrate a clear path to positive net margins, the market may continue to apply a significant discount to its valuation relative to more stable peers.

XRAY — Frequently Asked Questions

Quick answers to the most common questions about buying XRAY stock.

What was DENTSPLY SIRONA Inc.'s (XRAY) revenue in 2025?

For fiscal year 2025, DENTSPLY SIRONA Inc. (XRAY) reported total revenue of $3.68B. This represents a 460.5% increase compared to $656.6M in 1996.

Is DENTSPLY SIRONA Inc. (XRAY) profitable?

DENTSPLY SIRONA Inc. (XRAY) reported a net loss of $598.0M for the fiscal year ending 2025.

What is DENTSPLY SIRONA Inc.'s operating profit margin?

DENTSPLY SIRONA Inc. (XRAY) reported an operating income of $252.0M, resulting in an operating profit margin of 6.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is DENTSPLY SIRONA Inc.'s gross profit and gross margin?

DENTSPLY SIRONA Inc. (XRAY) generated $1.84B in gross profit for the year, representing a gross profit margin of 50.0%. This demonstrates the company's core pricing power and production efficiency.